Search Results

You are looking at 121 - 130 of 199 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

Nadeem Abu-Rustum, Catheryn Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, and Shaili Aggarwal

supplemental estrogen, and high-fat diet), early age at menarche, nulliparity, late age at menopause, Lynch syndrome, ages between 55 and 64 years, and tamoxifen use. 1 – 6 Data show that almost 67% of patients with adenocarcinoma of the endometrium are

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead

adjuvant tamoxifen experienced the greatest benefit with the combination endocrine therapy. The reason for the divergent outcomes in the 2 studies is not known. NCCN Guidelines Insights : Metastatic Breast Cancer, Version 1.2012 Version 1

Full access

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

population suggesting very young women (age <35 years) are less likely to benefit from adjuvant hormone therapy, perhaps due to de novo tamoxifen resistance, highlighting the need to develop better therapies for this population. 6 Based on the results of the

Full access

Oral Chemotherapy Program Improves Adherence and Reduces Medication Wastage and Hospital Admissions

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein, and Cheryl Pegus

cohort completed the 5-year course of tamoxifen treatment. A recent survey of managed care organizations showed that approximately 45% of oral chemotherapy is dispensed through retail pharmacy channels, 31% through specialty pharmacies, 16% through mail

Full access

Pregnancy Screening in Patients With Cancer

Annika M. Gustafson, Deborah J. Goldfrank, William A. Dunson, Daniel L. Mulkerin, Rebecca L. Caires, and Keith D. Eaton

can result in lowered IQ and fetal malformation, depending on gestational age of the fetus and exposure level. 6 Hormonal treatments such as tamoxifen can result in a high frequency of congenital abnormalities, requiring the use of reliable birth

Full access

Uterine Neoplasms

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

– 1744 . 79 Quinn MA Campbell JJ . Tamoxifen therapy in advanced/recurrent endometrial carcinoma . Gynecol Oncol 1989 ; 32 : 1 – 3 . 80 Thigpen T Brady MF Homesley HD . Tamoxifen in the treatment of advanced or recurrent

Full access

Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score

Hsiao-Ching Huang, Gregory S. Calip, Jennifer Weiss, Yael Simons, V.K. Gadi, Oana C. Danciu, Garth H. Rauscher, and Kent F. Hoskins

Cancer Inst 1996 ; 88 : 1456 – 1466 . 4. Paik S , Shak S , Tang G , A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer . N Engl J Med 2004 ; 351 : 2817 – 2826 . 5. Teutsch SM , Bradley LA

Full access

Updates to the Management of HR-Positive, HER2-Negative Breast Cancer

Presented by: William J. Gradishar

(as opposed to tamoxifen) has been positive, 22 but the OS benefit remains an open question, he added. Adjuvant CDK4/6 Inhibitors and Looking Ahead In the adjuvant setting, the CDK4/6 inhibitors abemaciclib and ribociclib have shown benefit

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

) than those who did not receive maintenance hormone therapy (median PFS, 64.9 vs 26.4 months; P <.001). 40 Most patients in the study received letrozole (54.3%), with a lower proportion receiving tamoxifen (28.6%). Based on these data, maintenance

Full access

Are New Oral Anticoagulants Ready for Use in Patients With Cancer?

Paul C. Hendrie and David A. Garcia

cancer mortality is not known. Other factors, such as venous stasis from vessel compression, immobility, central venous catheters (CVC), and thrombogenic anticancer therapies, such as tamoxifen and thalidomide, play a role in some patients. The new agents